Hims & Hers Health (NYSE:HIMS) Price Target Raised to $24.00

Hims & Hers Health (NYSE:HIMS) had its target price raised by Piper Sandler from $21.00 to $24.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.80.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $25.74 on Monday. The firm has a 50-day simple moving average of $26.97 and a two-hundred day simple moving average of $21.59. Hims & Hers Health has a fifty-two week low of $8.14 and a fifty-two week high of $35.02. The company has a market cap of $5.62 billion, a P/E ratio of 58.50 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the firm posted ($0.04) EPS. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the completion of the sale, the insider now owns 184,947 shares of the company’s stock, valued at $6,206,821.32. This trade represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 269,739 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the transaction, the chief financial officer now directly owns 145,763 shares in the company, valued at approximately $2,960,446.53. This trade represents a 64.92 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,333,446 shares of company stock valued at $34,175,197. 17.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of HIMS. Quest Partners LLC increased its position in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares during the last quarter. CWM LLC increased its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Arizona State Retirement System raised its position in Hims & Hers Health by 3.0% in the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares during the period. Victory Capital Management Inc. raised its position in Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after purchasing an additional 1,212 shares during the period. Finally, Rockefeller Capital Management L.P. lifted its stake in Hims & Hers Health by 5.8% during the third quarter. Rockefeller Capital Management L.P. now owns 33,775 shares of the company’s stock worth $622,000 after purchasing an additional 1,864 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.